Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. Palmer, A. J., Valentine, W. J., Ray, J. A., Roze, S., & Muszbek, N. The European journal of health economics: HEPAC: health economics in prevention and care, 8(2):161–168, June, 2007. doi abstract bibtex To perform a health economic analysis on treatment with irbesartan in patients with type 2 diabetes and hypertension. A Markov model was adapted to the Hungarian setting to simulate renal deterioration from the development of microalbuminuria to nephropathy, doubling of serum creatinine, end-stage renal disease (ESRD) and all-cause mortality. Outcomes for two treatments were evaluated: (1) a placebo regimen of standard antihypertensive medications, and (2) the addition of irbesartan 300 mg administered daily, with both treatment initiated after developing microalbuminuria. Outcomes were discounted at 5% annually to correspond with national guidelines. Treatment with irbesartan was estimated to improve undiscounted life expectancy by 0.98 +/- 0.05 years, reduce the cumulative incidence of ESRD by 7.5 +/- 0.4%, and reduce lifetime costs by Hungarian Forints (HUF) 519,993 +/- 70,814, compared to placebo. Irbesartan was projected to improved life expectancy and reduce costs compared to placebo in the Hungarian setting in hypertensive patients with type 2 diabetes and microalbuminuria.
@article{palmer_health_2007-1,
title = {Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a {Hungarian} analysis},
volume = {8},
issn = {1618-7598},
shorttitle = {Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease},
doi = {10.1007/s10198-006-0033-2},
abstract = {To perform a health economic analysis on treatment with irbesartan in patients with type 2 diabetes and hypertension. A Markov model was adapted to the Hungarian setting to simulate renal deterioration from the development of microalbuminuria to nephropathy, doubling of serum creatinine, end-stage renal disease (ESRD) and all-cause mortality. Outcomes for two treatments were evaluated: (1) a placebo regimen of standard antihypertensive medications, and (2) the addition of irbesartan 300 mg administered daily, with both treatment initiated after developing microalbuminuria. Outcomes were discounted at 5\% annually to correspond with national guidelines. Treatment with irbesartan was estimated to improve undiscounted life expectancy by 0.98 +/- 0.05 years, reduce the cumulative incidence of ESRD by 7.5 +/- 0.4\%, and reduce lifetime costs by Hungarian Forints (HUF) 519,993 +/- 70,814, compared to placebo. Irbesartan was projected to improved life expectancy and reduce costs compared to placebo in the Hungarian setting in hypertensive patients with type 2 diabetes and microalbuminuria.},
language = {eng},
number = {2},
journal = {The European journal of health economics: HEPAC: health economics in prevention and care},
author = {Palmer, A. J. and Valentine, W. J. and Ray, J. A. and Roze, S. and Muszbek, N.},
month = jun,
year = {2007},
pmid = {17237927},
keywords = {Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Chronic, Cohort Studies, Combination, Comorbidity, Costs and Cost Analysis, Diabetes mellitus, Diabetes Mellitus, Drug Therapy, Humans, Hungary, Hypertension, Irbesartan, Kidney Failure, Life Expectancy, Markov Chains, Middle Aged, Outcome Assessment (Health Care), Tetrazoles, Type 2},
pages = {161--168},
}
Downloads: 0
{"_id":"J9yDWwwuwGzvETBtu","bibbaseid":"palmer-valentine-ray-roze-muszbek-healtheconomicimplicationsofirbesartantreatmentversusstandardbloodpressurecontrolinpatientswithtype2diabeteshypertensionandrenaldiseaseahungariananalysis-2007","author_short":["Palmer, A. J.","Valentine, W. J.","Ray, J. A.","Roze, S.","Muszbek, N."],"bibdata":{"bibtype":"article","type":"article","title":"Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis","volume":"8","issn":"1618-7598","shorttitle":"Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease","doi":"10.1007/s10198-006-0033-2","abstract":"To perform a health economic analysis on treatment with irbesartan in patients with type 2 diabetes and hypertension. A Markov model was adapted to the Hungarian setting to simulate renal deterioration from the development of microalbuminuria to nephropathy, doubling of serum creatinine, end-stage renal disease (ESRD) and all-cause mortality. Outcomes for two treatments were evaluated: (1) a placebo regimen of standard antihypertensive medications, and (2) the addition of irbesartan 300 mg administered daily, with both treatment initiated after developing microalbuminuria. Outcomes were discounted at 5% annually to correspond with national guidelines. Treatment with irbesartan was estimated to improve undiscounted life expectancy by 0.98 +/- 0.05 years, reduce the cumulative incidence of ESRD by 7.5 +/- 0.4%, and reduce lifetime costs by Hungarian Forints (HUF) 519,993 +/- 70,814, compared to placebo. Irbesartan was projected to improved life expectancy and reduce costs compared to placebo in the Hungarian setting in hypertensive patients with type 2 diabetes and microalbuminuria.","language":"eng","number":"2","journal":"The European journal of health economics: HEPAC: health economics in prevention and care","author":[{"propositions":[],"lastnames":["Palmer"],"firstnames":["A.","J."],"suffixes":[]},{"propositions":[],"lastnames":["Valentine"],"firstnames":["W.","J."],"suffixes":[]},{"propositions":[],"lastnames":["Ray"],"firstnames":["J.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Roze"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Muszbek"],"firstnames":["N."],"suffixes":[]}],"month":"June","year":"2007","pmid":"17237927","keywords":"Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Chronic, Cohort Studies, Combination, Comorbidity, Costs and Cost Analysis, Diabetes mellitus, Diabetes Mellitus, Drug Therapy, Humans, Hungary, Hypertension, Irbesartan, Kidney Failure, Life Expectancy, Markov Chains, Middle Aged, Outcome Assessment (Health Care), Tetrazoles, Type 2","pages":"161–168","bibtex":"@article{palmer_health_2007-1,\n\ttitle = {Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a {Hungarian} analysis},\n\tvolume = {8},\n\tissn = {1618-7598},\n\tshorttitle = {Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease},\n\tdoi = {10.1007/s10198-006-0033-2},\n\tabstract = {To perform a health economic analysis on treatment with irbesartan in patients with type 2 diabetes and hypertension. A Markov model was adapted to the Hungarian setting to simulate renal deterioration from the development of microalbuminuria to nephropathy, doubling of serum creatinine, end-stage renal disease (ESRD) and all-cause mortality. Outcomes for two treatments were evaluated: (1) a placebo regimen of standard antihypertensive medications, and (2) the addition of irbesartan 300 mg administered daily, with both treatment initiated after developing microalbuminuria. Outcomes were discounted at 5\\% annually to correspond with national guidelines. Treatment with irbesartan was estimated to improve undiscounted life expectancy by 0.98 +/- 0.05 years, reduce the cumulative incidence of ESRD by 7.5 +/- 0.4\\%, and reduce lifetime costs by Hungarian Forints (HUF) 519,993 +/- 70,814, compared to placebo. Irbesartan was projected to improved life expectancy and reduce costs compared to placebo in the Hungarian setting in hypertensive patients with type 2 diabetes and microalbuminuria.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {The European journal of health economics: HEPAC: health economics in prevention and care},\n\tauthor = {Palmer, A. J. and Valentine, W. J. and Ray, J. A. and Roze, S. and Muszbek, N.},\n\tmonth = jun,\n\tyear = {2007},\n\tpmid = {17237927},\n\tkeywords = {Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Chronic, Cohort Studies, Combination, Comorbidity, Costs and Cost Analysis, Diabetes mellitus, Diabetes Mellitus, Drug Therapy, Humans, Hungary, Hypertension, Irbesartan, Kidney Failure, Life Expectancy, Markov Chains, Middle Aged, Outcome Assessment (Health Care), Tetrazoles, Type 2},\n\tpages = {161--168},\n}\n\n","author_short":["Palmer, A. J.","Valentine, W. J.","Ray, J. A.","Roze, S.","Muszbek, N."],"bibbaseid":"palmer-valentine-ray-roze-muszbek-healtheconomicimplicationsofirbesartantreatmentversusstandardbloodpressurecontrolinpatientswithtype2diabeteshypertensionandrenaldiseaseahungariananalysis-2007","role":"author","urls":{},"keyword":["Albuminuria","Antihypertensive Agents","Biphenyl Compounds","Chronic","Cohort Studies","Combination","Comorbidity","Costs and Cost Analysis","Diabetes mellitus","Diabetes Mellitus","Drug Therapy","Humans","Hungary","Hypertension","Irbesartan","Kidney Failure","Life Expectancy","Markov Chains","Middle Aged","Outcome Assessment (Health Care)","Tetrazoles","Type 2"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","dataSources":["ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","zeMwFvgpdRkYAkfoD","v8uQmZsBpiqycmskv"],"keywords":["albuminuria","antihypertensive agents","biphenyl compounds","chronic","cohort studies","combination","comorbidity","costs and cost analysis","diabetes mellitus","diabetes mellitus","drug therapy","humans","hungary","hypertension","irbesartan","kidney failure","life expectancy","markov chains","middle aged","outcome assessment (health care)","tetrazoles","type 2"],"search_terms":["health","economic","implications","irbesartan","treatment","versus","standard","blood","pressure","control","patients","type","diabetes","hypertension","renal","disease","hungarian","analysis","palmer","valentine","ray","roze","muszbek"],"title":"Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis","year":2007}